Reska Biotech

Reska Biotech ROE

The Return on Equity (ROE) of Reska Biotech (GWIN) as of Nov 9, 2026 is 21.72 %. In the previous year, Return on Equity (ROE) was 12.88 % — a change of 68.56% (higher).

ROE

21.72 %

YoY

68.56%

Last updated:

In 2022, Reska Biotech's return on equity (ROE) was 21.72 %, a 68.56% increase from the 12.88 % ROE in the previous year.

The Reska Biotech ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-489.63 USD
Jan 1, 2016
8,822.88 USD
Jan 1, 2017
2,082.94 USD
Jan 1, 2018
12.88 USD
Jan 1, 2022
21.72 USD
The Reska Biotech ROE history
YEARROEYoY
21.72 %+68.56%
12.88 %-99.38%
2,082.94 %-76.39%
8,822.88 %-1,901.95%
-489.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Reska Biotech Stock analysis

What does Reska Biotech do? The Glorywin Entertainment Group Inc is a Hong Kong-based company that specializes in the production, management, and marketing of entertainment content. The company was founded in 2005 and has been listed on the Canadian stock exchange since 2015. Glorywin's business model is based on the production and marketing of entertainment content in various sectors. This includes film and television production, music labels, event management, as well as the management and marketing of artists and celebrities. Over the years, the company has developed and produced a variety of products. In the film and television sector, these include TV series such as "The Four Detective Guards," "Journey to the East," "Ten Deadly Sins," and "Saviors in the Forbidden City." In addition, Glorywin has also produced films for the cinema such as "The Four," "Kung Fu Angels," and "The White Storm." Musically, the company is primarily active in the Asian pop industry and operates its own label with well-known artists such as Coco Lee and Janice Vidal. Another important business area for Glorywin is event management. The company organizes concerts, festivals, and other events in China and other Asian countries. The most well-known events include the "MTV Super Summit," the "Pepsi Music Festival," and the "Hong Kong Asian-Pop Music Festival." Glorywin often collaborates with other companies to reach a wider audience. In addition to the production of entertainment content and event management, Glorywin also operates its own leisure facilities. The goal is to make the brand and products of the company accessible to a broader audience. The company primarily focuses on theme parks and interactive museums. Currently, Glorywin operates the "Three Kingdoms City" theme park in China and the "Cool & Ice World" museum in Hong Kong. In recent years, the company has also focused on the digital media sector. Glorywin operates its own social media platform for fans and has developed a chatbot system for interactive communication with customers. The goal is to position and market the brand and products even more strongly in the digital world. To coordinate and manage all these activities, Glorywin has built an experienced team of managers and producers. The company works closely with international partners and collaborators to develop innovative products and events that excite the audience and tap into new markets. Overall, the company has become an important player in the Asian entertainment industry in recent years and has achieved numerous successes. This success is supported by the increasing popularity of Asian pop music, TV series, and films worldwide. In the future, Glorywin will likely continue to focus on these trends and attempt to establish itself in new markets. Reska Biotech is one of the most popular companies on Eulerpool.

ROE Details

Decoding Reska Biotech's Return on Equity (ROE)

Reska Biotech's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Reska Biotech's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Reska Biotech's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Reska Biotech’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Reska Biotech stock

Return on Equity (ROE) of Reska Biotech is 21.72 % in 2022.

Return on Equity (ROE) of Reska Biotech changed from 12.88 % to 21.72 %, representing a 68.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Reska Biotech since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Reska Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Reska Biotech

All Key Metrics — Reska Biotech